Symptomatic treatment of multiple sclerosis

被引:104
|
作者
Henze, T.
Rieckmann, P.
Toyka, K. V.
机构
[1] Reha Zentrum Nittenau, Rehabil Zentrum Neurol, DE-93149 Nittenau, Germany
[2] Univ Wurzburg, Dept Neurol, D-8700 Wurzburg, Germany
关键词
multiple sclerosis; symptomatic treatment; consensus guidelines; expert opinion; evidence-based medicine;
D O I
10.1159/000095699
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Besides immunomodulation and immunosuppression, the specific treatment of symptoms is an essential component of the overall management of multiple sclerosis (MS). Symptomatic treatment is aimed at the elimination or reduction of symptoms impairing the functional abilities and quality of life of the affected patients. Moreover, with symptomatic treatment the development of a secondary physical impairment due to an existing one may be avoided. Many therapeutic techniques as well as different drugs are used for the treatment of MS symptoms, but only a few of them have been investigated, especially in MS patients, and are approved by the national health authorities. Despite an overwhelming number of publications, only a few evidence-based studies exist and consensus reports are very rare, too. Therefore, it seemed necessary to develop a consensus statement on symptomatic treatment of MS comprising existing evidence-based literature as well as therapeutic experience of neurologists who have dealt with these problems over a long time. This consensus paper contains proposals for the treatment of the most common MS symptoms: disorders of motor function and coordination, of cranial nerve function, of autonomic, cognitive, and psychological functions as well as MS-related pain syndromes and epileptic seizures. Copyright (c) 2006 S. Karger AG, Basel.
引用
收藏
页码:78 / 105
页数:28
相关论文
共 50 条
  • [31] Preliminary evaluation of lowering tympanic temperature for the symptomatic treatment of multiple sclerosis
    Syndulko, K
    Woldanski, A
    Baumhefner, RW
    Tourtellotte, WW
    JOURNAL OF NEUROLOGIC REHABILITATION, 1995, 9 (04): : 205 - 215
  • [32] The Role of Fampridine in the Symptomatic Treatment of Gait Impairment in Patients with Multiple Sclerosis
    Piwonski, Michal
    Zak, Klaudia
    Gierszon, Patrycja
    Morawska, Izabela
    Psiuk, Dominika
    Stachura, Agata
    ACTA BALNEOLOGICA, 2019, 61 (03): : 199 - 207
  • [33] Symptomatic treatment in multiple sclerosis-interim analysis of a nationwide registry
    Skierlo, S.
    Rommer, P. S.
    Zettl, U. K.
    ACTA NEUROLOGICA SCANDINAVICA, 2017, 135 (04): : 394 - 399
  • [34] Symptomatic management and rehabilitation in multiple sclerosis
    Thompson, AJ
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2001, 71 : II22 - II27
  • [35] Symptomatic therapy and neurorehabilitation in multiple sclerosis
    Kesselring, J
    Beer, S
    LANCET NEUROLOGY, 2005, 4 (10): : 643 - 652
  • [36] SYMPTOMATIC THERAPY OF MULTIPLE-SCLEROSIS
    SCHAPIRO, RT
    LANGER, SL
    CURRENT OPINION IN NEUROLOGY, 1994, 7 (03) : 229 - 233
  • [37] Symptomatic medication use in multiple sclerosis
    Brichetto, G
    Uccelli, MM
    Mancardi, GL
    Solaro, C
    MULTIPLE SCLEROSIS, 2003, 9 (05): : 458 - 460
  • [38] Betaserc in symptomatic therapy of multiple sclerosis
    Boiko, AN
    Derevianko, SN
    Luchikhin, LA
    Slanova, AV
    Gusev, EI
    ZHURNAL NEVROPATOLOGII I PSIKHIATRII IMENI S S KORSAKOVA, 2002, 102 (01): : 42 - 45
  • [39] Symptomatic intraocular inflammation in multiple sclerosis
    Towler, HM
    Lightman, S
    CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2000, 28 (02): : 97 - 102
  • [40] Cannabinoids for symptomatic therapy of multiple sclerosis
    Husseini, L.
    Leussink, V. I.
    Warnke, C.
    Hartung, H. -P.
    Kieseier, B. C.
    NERVENARZT, 2012, 83 (06): : 695 - +